Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896;2:104–107.

• PubMed
BeatsonGT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896;2:104–107. )| false
• Search Google Scholar
• Export Citation

Fisher B, Costantino JP, Wickerham DL et al.. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371–1388.

• PubMed
FisherBCostantinoJPWickerhamDL. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371–1388. )| false
• Search Google Scholar
• Export Citation

Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998;351:1451–1467.

• PubMed
Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998;351:1451–1467. )| false
• Search Google Scholar
• Export Citation

Smith IE. Drug therapy: aromatase inhibitors in breast cancer. N Engl J Med 2003;348:2431–2442.

• PubMed
SmithIE. Drug therapy: aromatase inhibitors in breast cancer. N Engl J Med 2003;348:2431–2442. )| false
• Search Google Scholar
• Export Citation

Kaufmann M, Bajetta E, Dirix LY et al.. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 2000;18:1399–1411.

• PubMed
KaufmannMBajettaEDirixLY. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 2000;18:1399–1411. )| false
• Search Google Scholar
• Export Citation

Bonneterre J, Buzdar A, Nabholtz JMA et al.. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001;92:2247–2258.

• PubMed
BonneterreJBuzdarANabholtzJMA. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001;92:2247–2258. )| false
• Search Google Scholar
• Export Citation

Nabholtz JMA, Buzdar A, Pollak M et al.. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 2000;18:3758–3767.

• PubMed
NabholtzJMABuzdarAPollakM. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 2000;18:3758–3767. )| false
• Search Google Scholar
• Export Citation

Mouridsen H, Gershanovich M, Sun Y et al.. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;10:2596–2606.

• PubMed
MouridsenHGershanovichMSunY. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;10:2596–2606. )| false
• Search Google Scholar
• Export Citation

Mouridsen H, Gershanovich M, Sun Y et al.. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101–2109.

• PubMed
MouridsenHGershanovichMSunY. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101–2109. )| false
• Search Google Scholar
• Export Citation

Paridaens R, Dirix L, Lohrisch C et al.. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003;14:1391–1398.

• PubMed
ParidaensRDirixLLohrischC. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003;14:1391–1398. )| false
• Search Google Scholar
• Export Citation

Paridaens R, Therasse P, Dirix L et al.. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts): a randomized phase III trial of the EORTC Breast Group (Abstr #515). Proc Am Soc Clin Oncol 2004;23.

• PubMed
ParidaensRTherassePDirixL. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts): a randomized phase III trial of the EORTC Breast Group (Abstr #515). Proc Am Soc Clin Oncol 2004;23. )| false
• Search Google Scholar
• Export Citation

Carlson RW, Edge SB, McCormick B, Theriault R et al.. Clinical Practice Guidelines in Oncology version 1.2005. National Comprehensive Cancer Network. Available at http://www.nccn.org. Accessed April 18, 2005.

• PubMed
CarlsonRWEdgeSBMcCormickBTheriaultR. Clinical Practice Guidelines in Oncology version 1.2005. National Comprehensive Cancer Network. Available at http://www.nccn.org. Accessed April 18, 2005. )| false
• Search Google Scholar
• Export Citation

Baum M, Buzdar A, Cuzick J et al.. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 2002;359:2131–2139.

• PubMed
BaumMBuzdarACuzickJ. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 2002;359:2131–2139. )| false
• Search Google Scholar
• Export Citation

Baum M, Buzdar A, Cuzick J et al.. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802–1810.

• PubMed
BaumMBuzdarACuzickJ. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802–1810. )| false
• Search Google Scholar
• Export Citation

The ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60–62.

• PubMed
The ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60–62. )| false
• Search Google Scholar
• Export Citation

Winer EP, Hudis C, Burstein HJ et al.. American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23:619–629.

• PubMed
WinerEPHudisCBursteinHJ. American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23:619–629. )| false
• Search Google Scholar
• Export Citation

Fisher B, Dignam J, Bryant J et al.. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 2001;93:684–690.

• PubMed
FisherBDignamJBryantJ. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 2001;93:684–690. )| false
• Search Google Scholar
• Export Citation

Goss PE, Ingle JN, Martino S et al.. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793–1802.

• PubMed
GossPEIngleJNMartinoS. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793–1802. )| false
• Search Google Scholar
• Export Citation

Coombes RC, Hall E, Gibson LJ et al.. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081–1092.

• PubMed
CoombesRCHallEGibsonLJ. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081–1092. )| false
• Search Google Scholar
• Export Citation

Eiermann W, Paepke S, Appfelstaedt J et al.. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001;12:1527–1532.

• PubMed
EiermannWPaepkeSAppfelstaedtJ. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001;12:1527–1532. )| false
• Search Google Scholar
• Export Citation

Semiglazov VF, Semiglazov VV, Ivanov VG et al.. Neoadjuvant endocrine therapy: exemestane (E) vs. tamoxifen (T) in postmenopausal ER+ breast cancer patients (T1-4 N1-2 MO) (Abstr #111). Breast Cancer Res Treat 2003;83(suppl 1):S22.

• PubMed
SemiglazovVFSemiglazovVVIvanovVG. Neoadjuvant endocrine therapy: exemestane (E) vs. tamoxifen (T) in postmenopausal ER+ breast cancer patients (T1-4 N1-2 MO) (Abstr #111). Breast Cancer Res Treat 2003;83(suppl 1):S22. )| false
• Search Google Scholar
• Export Citation

Singletary SE, Allred C, Ashley P et al.. Revision of the American Joint Committee on Cancer Staging System for Breast Cancer. J Clin Oncol 2002;20:3628–3636.

• PubMed
SingletarySEAllredCAshleyP. Revision of the American Joint Committee on Cancer Staging System for Breast Cancer. J Clin Oncol 2002;20:3628–3636. )| false
• Search Google Scholar
• Export Citation

Semiglazov VF, Ivanov VG, Semiglazov VV et al.. Neoadjuvant endocrine therapy vs. chemotherapy for postmenopausal ER-positive breast cancer patients. Poster presentation at San Antonio Breast Conference, San Antonio, TX; December 9, 2004.

• PubMed
SemiglazovVFIvanovVGSemiglazovVV. Neoadjuvant endocrine therapy vs. chemotherapy for postmenopausal ER-positive breast cancer patients. Poster presentation at San Antonio Breast Conference, San Antonio, TX; December 9, 2004. )| false
• Search Google Scholar
• Export Citation

Rose C, Vtoraya O, Pluzanska A et al.. An open randomized trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 2003;39:2318–2327.

• PubMed
RoseCVtorayaOPluzanskaA. An open randomized trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 2003;39:2318–2327. )| false
• Search Google Scholar
• Export Citation

Dunn BK, Wickerham DL, Ford LG. Prevention of hormone-related cancers: breast cancer. J Clin Oncol 2005;23:357–367.

• PubMed
DunnBKWickerhamDLFordLG. Prevention of hormone-related cancers: breast cancer. J Clin Oncol 2005;23:357–367. )| false
• Search Google Scholar
• Export Citation